Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database.

HOME
>
論文・技術情報
>
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database.

アブストラクト
ジャーナル名	Allergy
投稿日	2021/7/17
投稿者	Mota, Diogo; Rama, Tiago Azenha; Severo, Milton; Moreira, Andre
組織名	Servico de Imunoalergologia, Centro Hospitalar Universitario de Sao Joao, Porto,;Portugal.;Servico de Imunologia Basica e Clinica, Faculdade de Medicina da Universidade do;Porto, Portugal.;EPIUnit, Instituto de Saude Publica, e Laboratorio para a Investigacao;Integrativa e Translacional em Saude Populacional (ITR), Universidade do Porto,
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/34270120/